Starting July 1, 2026, eligible Medicare patients with obesity can access Wegovy (semaglutide) for a $50 monthly copay through the new Medicare GLP-1 Bridge program. This initiative, in partnership with Novo Nordisk, covers all Wegovy doses and forms nationwide until the end of 2027, expanding access to FDA-approved obesity treatments. Meanwhile, Amazon Pharmacy is enhancing access to the oral Ozempic pill with same-day delivery and in-office pickup options, making diabetes treatment more convenient for insured customers.
Wells Fargo's economist forecasts GLP-1 weight-loss drugs like Ozempic and Mounjaro will reach about 90 million prescriptions, rivaling statins. This trend is driving demand for high-protein, low-volume foods suited for appetite-suppressed patients, ...
Novo Nordisk is rated a strong buy, offering a 4.2% dividend yield and trading at a 40% discount to its fair value. Although growth is currently pressured by U.S. price cuts and competition, the company is expected to achieve double-digit growth from...
Bitcoin dropped to its lowest level since February, falling as much as 2.3% due to record outflows from spot Bitcoin ETFs totaling $2.3 to $2.8 billion and weakening institutional demand. Strategy's sale of 32 bitcoins, its first in nearly four years...
Novo Nordisk has launched the Wegovy pill in the United Arab Emirates, marking the first availability outside the US. The pill, containing semaglutide, is approved to reduce excess body weight by an average of 17% and lower the risk of major cardiova...
Novo Nordisk's oral GLP-1 weight-loss drug, Wegovy pill, continues to outsell Eli Lilly's competing tablet, Foundayo, with around 146,000 prescriptions in the week ending May 22. However, weekly prescription growth has slowed to 2% as the market adju...
